Breaking News
March 22, 2018 - Vitamin D deficiency linked to metabolic syndrome in postmenopausal women
March 22, 2018 - Changes in the intestines may be responsible for reversal of diabetes after bariatric surgery
March 22, 2018 - iPads and Cancer; Clot Retrieval and Stroke: It’s PodMed Double T!
March 22, 2018 - Premature births linked to changes in mother’s bacteria
March 22, 2018 - Brain SPECT scans predict treatment outcomes in patients with depression
March 21, 2018 - Researchers succeed in integrating artificial organelles into cells of living organism
March 21, 2018 - Researchers discover ‘missing mutation’ in severe infant epilepsy
March 21, 2018 - Researchers develop statistics-based computational scheme to zoom in on brain function
March 21, 2018 - Verge joins Genomics England’s Discovery Forum industry partnership
March 21, 2018 - Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
March 21, 2018 - Congenital Cardiac Cath Tx Often Strays from Guidelines
March 21, 2018 - Marked increase in cardiovascular risk factors in women after preeclampsia
March 21, 2018 - New app may help predict, track manic and depressive episodes in bipolar patients
March 21, 2018 - Discovery of genes could lead to development of novel therapies for EBV-related cancers
March 21, 2018 - High-fat, high-cholesterol diet depletes ranks of artery-protecting immune cells
March 21, 2018 - Research misconduct allegations shadow likely CDC appointee
March 21, 2018 - Most Breast Ca Patients Fail to Get Genetic Counseling
March 21, 2018 - Lopsided ear function can lead to lopsided brain development
March 21, 2018 - Acupuncture helps manage menopausal symptoms, review finds
March 21, 2018 - Motor skill training may contribute to reading skills in obese children
March 21, 2018 - Poor dental health may be related to increased diabetes risk
March 21, 2018 - Chronic opioid users at increased risk of complications after spinal fusion surgery
March 21, 2018 - NSAID use linked to increased risk of atrial fibrillation
March 21, 2018 - Scientists develop brain “stethoscope” that can detect silent seizures
March 21, 2018 - New method predicts effects of global warming on disease
March 21, 2018 - Insurance Company Hurdles Burden Doctors, May Harm Patients
March 21, 2018 - Renal Transplant from HCV-Positive Donors Feasible
March 21, 2018 - Myelodysplastic syndrome: MedlinePlus Medical Encyclopedia
March 21, 2018 - Research reveals brain mechanism involved in language learning
March 21, 2018 - Many parents still hesitate to try early peanut introduction, survey finds
March 21, 2018 - Audiologist urges tinnitus sufferers facing ‘revolving door healthcare’ to seek support
March 21, 2018 - Study reveals impact of prostate cancer on wives and partners of sufferers
March 21, 2018 - ‘Almost a Miracle Drug’: What We Heard This Week
March 21, 2018 - Study shows NIH spent >$100 billion on basic science for new medicines
March 21, 2018 - Columbia researchers identify nerve cells that drive fruit fly’s escape behavior
March 21, 2018 - Sartorius Stedim Biotech selected by ABL Europe to supply single-use process technologies
March 21, 2018 - Increase in coffee consumption may help battle against colon cancer
March 21, 2018 - Hydrogel may accelerate healing of diabetic ulcers
March 21, 2018 - Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
March 21, 2018 - DePuy Synthes introduces ACTIS Total Hip System for improving initial implant stability
March 21, 2018 - ‘Oh, It Was Nothing’
March 21, 2018 - Herbal drug kratom linked to salmonella illnesses, CDC says
March 21, 2018 - New optical point-of-care device could enhance screening for thyroid nodules
March 21, 2018 - FDA Expands Approval of Adcetris (brentuximab vedotin) for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
March 21, 2018 - Eosinophilic Esophagitis: Late Manifestation of Allergic March
March 21, 2018 - Signaling pathway involving the Golgi apparatus identified in cells with Huntington’s disease
March 21, 2018 - Quintupling inhaled steroid doses may not benefit children with asthma
March 21, 2018 - Study shows clear connection between cardiovascular fitness in middle age and dementia risk
March 21, 2018 - Premature babies have higher risks of health complications in Bangladesh
March 21, 2018 - Child’s temperament and parenting influence weight gain in babies
March 21, 2018 - Researchers find the heart to be capable of arrhythmia termination after local gene therapy
March 21, 2018 - Inhealthcare to provide digital infrastructure for NHS to help protect people from falls
March 21, 2018 - Flu Season Finally Slowing Down
March 21, 2018 - Mixed Results for Shorter DAPT in ACS Patients
March 21, 2018 - Scientists discover fish scale-derived collagen effective for healing wounds
March 21, 2018 - Genomics England announces new partnership to improve efficiency of next-generation sequencing analysis
March 21, 2018 - Adjuvant AC chemotherapy found to be effective in treating HRD-positive breast cancer patients
March 21, 2018 - Researchers identify new treatment targets for lung diseases using big data
March 21, 2018 - Kids see more women in science than five decades ago
March 21, 2018 - Research shows link between chronic fatigue syndrome and lower thyroid hormone levels
March 21, 2018 - Alzheimer’s disease on the rise
March 21, 2018 - Two Agents Equal as Pretreatment for Adrenal Tumor Surgery
March 21, 2018 - ‘Icebreaker’ protein opens genome for T cell development, researchers find
March 21, 2018 - Women in medicine shout #Metoo about sexual harassment at work
March 21, 2018 - Mother’s pre-pregnancy waist size may be linked to child’s autism risk
March 21, 2018 - Second hand marijuana smoke can cause serious damage
March 21, 2018 - International study shows benefits of using MRI at the start of prostate cancer diagnosis
March 20, 2018 - Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
March 20, 2018 - ECG Patch Ups At-Home Afib Diagnosis in mSToPS Trial
March 20, 2018 - ROS-scavenging nanozymes for anti-inflammation therapeutics
March 20, 2018 - Genomics England announces appointment of global genomics pioneer as first CEO
March 20, 2018 - Test flight at German Aerospace Center in Cologne demonstrates functionality of deficopter
March 20, 2018 - Music therapy helps treat combat-related psychological injuries in military personnel
March 20, 2018 - Innovative psychotherapeutic treatment protocol for obsessive-compulsive disorders
March 20, 2018 - Weight loss after lap-band surgery alleviates arthritic knee pain
March 20, 2018 - New diabetes drug may help obese people shed body weight
March 20, 2018 - Novel Peanut OIT a Winner in Phase III Trial
March 20, 2018 - Can gene therapy be harnessed to fight the AIDS virus?
March 20, 2018 - Education and academic achievement can lessen effects of child abuse, neglect
March 20, 2018 - Researchers develop new algorithm to make CPR more effective
Combo Treatment Offers New Hope in Tough-to-Treat CLL

Combo Treatment Offers New Hope in Tough-to-Treat CLL

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • The combination treatment of ibrutinib (Imbruvica) with venetoclax (Venclexta) was well tolerated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
  • After 6 months of the combo therapy, 84% had no morphological evidence of CLL in the marrow biopsy, and 76% had less than 1% CLL cells in the marrow.

ATLANTA — The combination treatment of ibrutinib (Imbruvica) with venetoclax (Venclexta) was well tolerated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), researchers reported here.

In preliminary results from the CLARITY trial, 38 of 54 patients treated with the combination (IBR+VEN) responded to the therapy after 6 months, and 15 of those patients achieved a complete response, according to Peter Hillmen, MBChB, PhD, of the University of Leeds in England, and colleagues.

In addition, only two of 41 patients experienced biochemical tumor lysis syndrome (TLS) to date, they said in a presentation at the American Society of Hematology (ASH) meeting.

“Ibrutinib is an oral BTK-inhibitor affecting antigen-induced proliferation and cell adhesion/migration whilst venetoclax is a potent, highly selective, orally bioavailable Bcl-2 inhibitor affecting CLL cell survival,” the authors wrote. “Ibrutinib treatment leads to a rapid nodal response with re-distribution of CLL into the peripheral blood, whereas venetoclax leads to depletion of CLL cells to levels where they cannot be detected in some patients. Ibrutinib leads to reduction of anti-apoptotic molecules such as MCL1, hence theoretically potentiating the effect of venetoclax.”

The CLARITY trial is a feasibility study to investigate the safety and efficacy of the combination treatment in patients with relapsed/refractory CLL.

The trial enrolled 50 CLL patients who required therapy, and who had either relapsed within 3 years of chemoimmunotherapy (h fludarabine, cyclophosphamide, and rituximab or bendamustine and rituximab), or had 17p deletion and had failed at least one line of therapy.

After 8 weeks of ibrutinib monotherapy (420mg/day), venetoclax was added first at a dose of 10mg/day, with weekly escalations to 20mg, 50mg, 100mg, and 200mg. The final dose was 400mg/day. No TLS was seen for the first three patients starting at 10mg/day of venetoclax, so all subsequent patients began venetoclax at 20mg/day.

Hillmen told MedPage Today that the plan is to treat the patients with a complete response for another 6 months, and then take them off medication for CLL to determine if the remission is durable. “

We are just getting to the point now where we will be taking patients off medication,” he said. “We cannot detect residual disease that may be lingering, so we want to extend therapy another 6 months so we can decrease even this undetectable disease several logs lower to the point that the disease may not ever come back.”

There were 37 men and 17 women in the study with a median age of 62. About 92% of the patients were in ECOG performance status of 0 or 1.

The trial’s primary endpoint is minimal residual disease (MRD) eradication, defined as <1 CLL cell in 104 assessed by 8-color flow in the marrow after 12 months of combination therapy. A key secondary endpoints is safety, with laboratory and clinical TLS defined as critical safety events, the authors explained.

All of the patients were given prophylactic uric acid-reducing agents beginning at least 72 hours prior to starting venetoclax, the authors noted. Over the first 3 months of combined therapy, the level of CLL in the peripheral blood was monitored weekly during venetoclax escalation and then every month after that.

The authors reported that the median number of prior therapies was two, including FCR or BR in 94%. Among 45 patients, 20% had 17p deleted, 27% had 11q deleted, and 77% had unmutated VH genes.

Of the two biochemical TLS events reported, one was an increase in creatinine and phosphate, and the other was an isolated phosphate increase, which did not meet the definition of TLS, according to the authors. Dosing of venetoclax was interrupted until the biochemical abnormalities resolved and these patients subsequently escalated to 400mg/day of venetoclax with no further TLS.

As for safety, there were five grade 3 or 4 infections, and 19 episodes of grade 3 or 4 neutropenia. All serious adverse events resolved with appropriate management and all patients remained on therapy following resolution. There were no fatal adverse events.

After 6 months of the combo therapy, 84% (21/25) had no morphological evidence of CLL in the marrow biopsy, and 76% had less than 1% CLL cells in the marrow. Also, 28% achieved an MRD negative remission (<10-4).

“Patients will continue IBR+VEN for the same duration of time as it took them to achieve MRD negativity (i.e. patients who are MRD negative after 6 months IBR+VEN will stop both drugs after 12 months of IBR+VEN). Therefore all patients will continue on IBR+VEN until at least the 14 month assessment (after 12 months of IBR+VEN),” the authors wrote.

“These early results suggest a potent synergy between ibrutinib and venetoclax,” they concluded.

ASH press conference moderator Laurie Sehn, MD, of the British Columbia Cancer Agency in Vancouver, called the results “truly exciting…we are moving towards an era where we can use these targeted therapies to replace some of the toxic agents used to treat hematological disorders.”

“When I trained, CLL was a boring disease to work with because it was a chronic condition, and there were limited treatment options,” she noted. “Now what we have seen with CLL has just been a explosion of an understanding of the disease that has resulted in drugs that have transformed our ability to treat patients. Data like this study are exactly where we want to see the field going. The ability to combine drugs rationally to make them work even better is exciting.”

She called the high response rate “highly impressive…It gives the promise that some of these patients may be cured. This is a first step in moving toward that direction.”

Hillmen disclosed relevant relationships with Gilead, Janssen, GSK, Celgene, AbbVie Company, Novartis, Roche, and Alexion Pharmaceuticals. Co-authors disclosed multiple relevant relationships with industry.

Sehn disclosed relevant relationships with Janssen, Amgen, Seattle Genetics, Abbvie, Celgene, and Roche/Genentech.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner


Tagged with:

About author

Related Articles